An interventional study of Sample collection in IBS, Ulcerative Colitis, Active and Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by KU Leuven · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one has the largest planned enrollment of the 168 interventional ones that give a count, is one of 3 that started in 2010, is one of 5 with no phase, reaches primary completion later than 49 of the 49 other live ones, and was the 56th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Belgium, United States, Germany and 2 more countries
Ages 18–60
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Sanofi · Sites in Belgium, United States, Argentina and 28 more countries
Ages 16–80
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 71 · Phase 3 82 · Phase 4 11
First in 2003; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99,999,999 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 198 across the 168 interventional studies, 280 across the 19 observational. Of the 134 that completed or were terminated, 80 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
160 of 187 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
12 of the studies in Colitis, Ulcerative with a site in Belgium that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim:
More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
Methods:
Sample collection in healthy subjects, IBD and IBS patients:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For group 1: IBS
Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Only for group 3a:
Group 4: Healthy controls No abdominal (pain) complaints.
Group 5: active Crohn's disease
1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
Exclusion Criteria:
For all groups:
Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
Other: Sample collection
Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
differences in visceral sensitivity in different study groups (Visceral sensitivity will me measured by performing a rectal barostat test)
Visceral sensitivity will me measured by performing a rectal barostat test
Time frame: at time of investigation (rectal barostat test), Day 1
immune activity (measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood)
measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood (for example by stimulating Peripheral Blood Mononuclear Cells)
Time frame: at time of investigation (rectal biopsy), Day 1
Started Mar 2010 (actual). Primary completion is estimated for Jan 2099, 1,066 months after the start.
Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 1,066 months is above that.
Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Feb 2010 → Mar 2010, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.